Fortress Biotech, Inc. (NASDAQ:FBIO) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01
The following exhibits are filed herewith:
| 10.1 | Underwriting Agreement, dated November 25, 2019, between Fortress Biotech, Inc., The Benchmark Company, LLC and ThinkEquity, a division of Fordham Financial Management, as representatives of the several underwriters named therein. |
| 5.1 | Opinion of Alston & Bird, LLP. |
| 23.1 | Consent of Alston & Bird, LLP (included in the opinion filed as Exhibit 5.1). |
| 99.1 | Press release issued by Fortress Biotech, Inc., dated November 25, 2019. |
Fortress Biotech, Inc. Exhibit
EX-5.1 2 tm1923896d1_ex5-1.htm EXHIBIT 5.1 Exhibit 5.1 90 Park Avenue New York,…
To view the full exhibit click here
About Fortress Biotech, Inc. (NASDAQ:FBIO)
Fortress Biotech, Inc., formerly Coronado Biosciences, Inc., is a biopharmaceutical company. The Company is involved in the development of immunotherapy agents for the treatment of autoimmune diseases and cancer. Its sole product candidate is CNDO-109. The Company is also focused on acquiring, developing and commercializing pharmaceutical and biotechnology products. The Company’s product, CNDO-109, is a lysate (disrupted Closteroviridae (CTV)-1 cells, cell membrane fragments, cell proteins and other cellular components) that activates donor Natural Killer (NK) cells. CTV-1 is a leukemic cell line re-classified as a T-cell acute lymphocytic leukemia (ALL). The Company holds the license to develop and commercialize CNDO-109 to activate NK cells for the treatment of cancer-related and other conditions, and a non-exclusive license to certain clinical data solely for use in the Investigational new drug (IND) for CNDO-109. The Company is conducting the Phase I clinical studies of CNDO-109.
